Sorafenib-resistant PTC showed the most noticeable variation of the cancer stemness marker (KRT17high, KRT19low, ALDH1A1high, PROM1[CD133]high, CD44high, CD24low, and SOX2high), FGF/FGFR (Fibroblast growth factor/Fibroblast growth factor receptors, FGF1, FGF5, FGF11, FGF13, FGF16, FGFR2, FGFR3, and FGFR4), and EMT (SNAIL1, SNAIL2, ZEB1, ZEB2, and TWIST1) (Figure 1B, top, middle, and bottom). This evidence concerns the gene FGF1 and cancer.